Piedmont Investment Advisors LLC Purchases 446 Shares of Alexion Pharmaceuticals, Inc. (ALXN)
Piedmont Investment Advisors LLC increased its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 1.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 46,533 shares of the biopharmaceutical company’s stock after buying an additional 446 shares during the quarter. Piedmont Investment Advisors LLC’s holdings in Alexion Pharmaceuticals were worth $5,662,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also recently added to or reduced their stakes in ALXN. Guardian Life Insurance Co. of America increased its stake in shares of Alexion Pharmaceuticals by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 6 shares during the period. Meeder Asset Management Inc. acquired a new position in shares of Alexion Pharmaceuticals in the first quarter valued at approximately $111,000. Fiduciary Trust Co. acquired a new position in shares of Alexion Pharmaceuticals in the second quarter valued at approximately $111,000. Huntington National Bank increased its stake in shares of Alexion Pharmaceuticals by 1,084.6% in the second quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 987 shares during the period. Finally, Penserra Capital Management LLC increased its stake in shares of Alexion Pharmaceuticals by 13.0% in the second quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 144 shares during the period. 94.25% of the stock is owned by institutional investors.
In related news, EVP Julie O’neill sold 11,160 shares of the company’s stock in a transaction on Monday, August 28th. The stock was sold at an average price of $140.00, for a total transaction of $1,562,400.00. Following the completion of the sale, the executive vice president now owns 26,704 shares in the company, valued at $3,738,560. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Ann M. Veneman sold 835 shares of the company’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total value of $121,751.35. Following the sale, the director now owns 5,480 shares of the company’s stock, valued at approximately $799,038.80. The disclosure for this sale can be found here. In the last quarter, insiders have sold 17,190 shares of company stock valued at $2,433,669. 4.35% of the stock is owned by company insiders.
Several research analysts have recently issued reports on ALXN shares. TheStreet raised Alexion Pharmaceuticals from a “c” rating to a “b-” rating in a research note on Friday, July 14th. SunTrust Banks, Inc. reaffirmed a “buy” rating and issued a $165.00 price objective on shares of Alexion Pharmaceuticals in a research note on Friday, July 14th. UBS AG reaffirmed a “buy” rating and issued a $142.00 price objective (up previously from $140.00) on shares of Alexion Pharmaceuticals in a research note on Monday, June 26th. BidaskClub upgraded Alexion Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, July 25th. Finally, Deutsche Bank AG reiterated a “buy” rating and issued a $158.00 target price (up from $153.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. Six investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $154.56.
Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) traded down 0.60% during midday trading on Friday, hitting $140.61. The stock had a trading volume of 721,653 shares. Alexion Pharmaceuticals, Inc. has a 12 month low of $96.18 and a 12 month high of $149.34. The stock’s 50-day moving average is $142.11 and its 200-day moving average is $127.08. The stock has a market cap of $31.38 billion, a PE ratio of 60.98 and a beta of 1.39.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.08 by $0.48. The firm had revenue of $912.00 million during the quarter, compared to analysts’ expectations of $846.15 million. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The company’s revenue was up 21.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.13 earnings per share. Equities analysts anticipate that Alexion Pharmaceuticals, Inc. will post $5.60 EPS for the current year.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.